UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
Veru Inc. MIAMI, July 25, 2022 (Globe NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical firm concentrated on developing novel medicines for COVID-19 and other viral and ARDS-related ailments and for the administration of breast and prostate cancers, these days declared that the United Kingdom’s (UK’s) Medicines and Healthcare Solutions Regulatory Agency (MHRA) considers that the currently available security and efficacy info will assist an expedited overview of the promoting authorization application for the Company’s sabizabulin treatment method in hospitalized…
